Head of Clinical Pharmacology
Galderma R&D
Dallas, Texas
Nathalie Wagner is currently the Head of Clinical Pharmacology at GALDERMA R&D, USA. In her current role, she is responsible for clinical pharmacology strategy in Therapeutic Dermatology, covering all phases from First in Human to late-stage development for both small molecules and therapeutic proteins (administered topically, orally, or by injection).
She has 35 years of experience in preclinical and clinical pharmacology, including PK, ADME, Model informed drug development (MIDD), pediatric plans, MUsT, DDI and TQT studies, and in vitro models. She frequently interfaces with regulatory agencies worldwide on pediatric plans, Clinical Pharmacology and Biopharmaceutical strategies. Over the past years, she contributed to numerous new drugs/biologics approvals worldwide, and one Rx-to-OTC switch in US.
Nathalie holds a Bachelor’s degree in Physiology from the University of Nice, France, and a Master’s degree in PK from the University of Toulouse, France. She participates in scientific work related to Therapeutic Dermatology and has contributed to congresses and publications in clinical pharmacology and MIDD. She is a former member and President of the French GMP Association (Pharmacokinetics and Metabolism group).
Disclosure information not submitted.
Nemolizumab: Pediatric Extrapolation to Waive Placebo-Controlled Studies in Atopic Dermatitis
Tuesday, November 11, 2025
3:45 PM - 4:00 PM CT